What are the side effects of Ocrelizumab?

Ocrelizumab (Ocrelizumab) is a humanized monoclonal antibody that specifically targets CD20-positive B cells, which are immune cells that play a key role in myelin and axonal damage in the nervous system. Orelizumab is mainly used to treat relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). Although the drug has achieved certain success in its therapeutic effect, its side effects also require attention.

In clinical studies, the most common adverse event with ocrelizumab was infusion reactions. These reactions may include symptoms such as itchy skin, rash, flushing, throat and mouth discomfort, fever, fatigue, nausea, rapid heartbeat, headache, and dizziness. These infusion reactions usually occur when taking the drug for the first time, and patients need to perform infusions under the guidance of a doctor so that possible reactions can be dealt with in a timely manner.

In addition to infusion reactions, the use of ocrelizumab is associated with several other potential side effects. One of them is an increased risk of infection. Because the drug inhibits the function ofB cells, patients may be more susceptible to infections such as viruses, bacteria, and fungi. In addition, patients taking ocrelizumab may develop progressive multifocal leukoencephalopathy (PML), a serious brain disease caused by the JC virus. Although this condition is relatively rare, it requires close monitoring.

During long-term use, ocrelizumab may cause a decrease in immunoglobulin levels, which may affect patients' immune function and make them more susceptible to infection. Studies have shown that some patients may develop malignant tumors after treatment, although this incidence is not high, and the medical community remains wary. At the same time, immune-mediated colitis is also a side effect that needs attention. If patients experience symptoms such as abdominal pain and diarrhea, they should seek medical treatment in time.

Reference materials:https://www.ocrevus.com/